NOTHING
IS SIMPLE
IN ONCOLOGY.

NOTHING BUT THIS.

BIOCARTIS

WHAT DOES IDYLLA™ MEAN FOR CANCER PATIENTS?

High Precision Diagnostics for Personalized Medicine

RAPID TREATMENT INITIATION[1]

Test results within 1-2 days

Molecular Testing in your hospital

MOLECULAR DIAGNOSTICS

- Melanoma
- Colorectal cancer
- Lung cancer
- RAS, BRAF, EGFR mutations MSI
- Solid & liquid biopsy[2]

BIOCARTIS

INTERNATIONAL COMPANY

Belgium based

+70 COUNTRIES

PHARMA COLLABORATIONS

AMGEN MERCK

idylla

(1) Idylla™ CE IVD Tests are capable of providing same day results intended to aid in the assessment of patients with cancer for their mutation status and to facilitate treatment decisions within a multidisciplinary team.

(2) Liquid biopsy assay not yet available for MSI.

IDYLLA™ PROVIDES ACCURATE, ACTIONABLE RESULTS WITH DIRECT IMPACT ON TREATMENT CHOICE[1]

- Idylla™ **solid biopsy** assays focus on **clinically relevant mutations**
- Clear reporting
- According to clinical guidelines of ASCO, ESMO, NCCN and IASLC*

THERAPEUTIC AREA	GENES	CLINICALLY RELEVANT MUTATIONS
	**BRAF**	7 mutations in codon 600
	**KRAS**	21 mutations in codons 12, 13, 59, 61, 117, 146
	NRAS	18 mutations in codons 12, 13, 59, 61, 117, 146
	BRAF	5 mutations in codon 600
	**EGFR**	51 mutations in exons 18, 19, 20, 21

(1) Idylla™ CE IVD Tests are capable of providing same day results intended to aid in the assessment of patients with cancer for their mutation status and to facilitate treatment decisions within a multidisciplinary team.

*Most recent guidelines can be found at:

- https://www.esmo.org/Guidelines
- https://www.asco.org/practice-guidelines/quality-guidelines/guidelines
- https://www.nccn.org/professionals/physician_gls/default.aspx
- https://www.iaslc.org/Research-Education/Publications/CAP-IASLC-AMP-Molecular-Testing-Guideline

IDYLLA™ LIQUID BIOPSY TESTING COULD TRANSFORM CANCER CARE

Idylla™ RAS liquid biopsy testing[1] (CE-IVD) can be used as an alternative or complement to tissue testing in clinical practice to determine the RAS mutation status at diagnosis for mCRC patients

Idylla™ ctKRAS and ctNRAS-BRAF liquid biopsy tests[1] show high plasma-tissue concordance in mCRC patients



tissue biopsy versus plasma biopsy

In clinical research liquid biopsies are currently used to monitor disease progression for various cancers

An increase in mutant ctDNA might give an (earlier) indication of resistance to treatment compared to CT scan



Idylla™ offers liquid biopsy assays directly on plasma for KRAS, NRAS, BRAF[2] & EGFR[2]

(1) Idylla™ ctKRAS Mutation Test and Idylla™ ctNRAS-BRAF Mutation Test are CE-marked IVD's.
(2) Idylla™ ctBRAF and ctEGFR Mutation Assays are for Research Use Only (RUO). Not for use in diagnostic procedures.

WHY WAIT WEEKS INSTEAD OF DAYS?

From sample to treatment initiation[1] in 1 to 2 days

MOLECULAR TESTING

TRADITIONAL WAY		IDYLLA™ WAY
In or outside your hospital • sending out samples • molecular infrastructure • molecular lab technicians	WHERE	**In your hospital** • in-house testing • any laboratory setting • all lab technicians
1-4 days turnaround time of test cumbersome workflow/manual steps **grouping of patient samples** 1/week or bi-weekly	HOW	**<2.5 hours turnaround time of test** fully automated **individual patient sample** on demand
on avg **18 days**[2,3]	WHEN	in **1-2 day(s)**[2,4]

(1) Idylla™ CE IVD Tests are capable of providing same day results intended to aid in the assessment of patients with cancer for their mutation status and to facilitate treatment decisions within a multidisciplinary team.

(2) Average waiting time including tissue pre-treatment & pathology review

(3) Accès aux tests moléculaires EGFR, RAS et BRAF /Résultats d'une enquête dans 5 régions françaises, appui à la décision, INCa, janvier 2016

(4) Ghigna M et al. Thorac Dis. 2018 Jul; 10(7): 4653-4658

IDYLLA™ CAN MAKE A DIFFERENCE IN YOUR PATIENT CARE

High Precision Diagnostics for Personalized Medicine

Test results within 1-2 days

Rapid treatment initiation[1]

Molecular testing in your hospital

Biocartis NV
Generaal de Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888
www.biocartis.com
customerservice@biocartis.com

Follow us on

(1) Idylla™ CE IVD Tests are capable of providing same day results intended to aid in the assessment of patients with cancer for their mutation status and to facilitate treatment decisions within a multidisciplinary team.

GL.BR002.EN.R4.10/2019